GWP42003-P + Placebo

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Tuberous Sclerosis Complex

Conditions

Tuberous Sclerosis Complex, Seizures

Trial Timeline

Apr 6, 2016 → Feb 26, 2019

NCT ID

NCT02544763

About GWP42003-P + Placebo

GWP42003-P + Placebo is a phase 3 stage product being developed by Jazz Pharmaceuticals for Tuberous Sclerosis Complex. The current trial status is completed. This product is registered under clinical trial identifier NCT02544763. Target conditions include Tuberous Sclerosis Complex, Seizures.

What happened to similar drugs?

1 of 7 similar drugs in Tuberous Sclerosis Complex were approved

Approved (1) Terminated (1) Active (5)

✅Cannabidiol Oral Solution [Epidiolex]Jazz PharmaceuticalsApproved

🔄Everolimus (RAD001) + Everolimus PlaceboNovartisPhase 3

🔄Everolimus + PlaceboNovartisPhase 3

🔄RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)NovartisPhase 3

🔄everolimusNovartisPhase 3

❌GWP42003-PJazz PharmaceuticalsPhase 3

🔄GWP42003-PJazz PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05288283	Phase 3	Terminated	Oct 31, 2022	Sep 28, 2023	Seizures Associated With EMAS
NCT04745026	Phase 2	Completed	May 31, 2021	Dec 21, 2023	Autism Spectrum Disorder
NCT04421456	Phase 2	Terminated	Aug 18, 2020	Mar 16, 2022	Schizophrenia
NCT03848832	Phase 3	Terminated	Jul 29, 2019	Jan 21, 2021	Rett Syndrome
NCT02607891	Phase 2	Completed	Nov 9, 2016	Oct 2, 2018	Epilepsy
NCT02544763	Phase 3	Completed	Apr 6, 2016	Feb 26, 2019	Tuberous Sclerosis Complex

Competing Products

13 competing products in Tuberous Sclerosis Complex

See all competitors

Product	Company	Stage	Hype Score
Everolimus (RAD001) + Everolimus Placebo	Novartis	Phase 3	40
Everolimus + Placebo	Novartis	Phase 3	40
RAD001	Novartis	Phase 1/2	32
Placebo + Everolimus (RAD001)	Novartis	Phase 2	31
RAD001 + Placebo	Novartis	Phase 2	35
RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase)	Novartis	Phase 3	40
Everolimus	Novartis	Phase 1/2	32
everolimus (RAD001)	Novartis	Phase 1/2	32
everolimus	Novartis	Phase 3	44
sirolimus	Pfizer	Phase 2	31
GWP42003-P	Jazz Pharmaceuticals	Phase 3	29
GWP42003-P	Jazz Pharmaceuticals	Phase 3	37
Cannabidiol Oral Solution [Epidiolex]	Jazz Pharmaceuticals	Approved	44